Targeted therapeutic approaches, including ALK inhibitors and anti-GD2 immunotherapy, have shown promising efficacy in improving clinical outcomes by addressing specific genetic mutations driving tumor growth [5]. This evidence concerns the gene ALK and neoplasm.